Clinical Trial Update: Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing 3-week and 4-week regimens of gemcitabine plus cisplatin in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED